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Abstract. It is known that PMA (phorbol-12-myristate-13-
acetate) can activate the classical and novel protein kinase C
isoenzymes (cPKC α, ß, γ and nPKC δ, ε, η, θ), while the
calcium ion can induce only the activity of cPKC. Calcineurin
binding protein (Cabin 1) belongs to the group of endogenous
inhibitors of calcineurin. Cabin 1 becomes hyperphos-
phorylated in response to PKC activation and may play a
negative role in calcineurin signalling. It was observed that
both PMA treatment and the increase in intracellular Ca2+
contributed to the reduction of calcineurin activity in human
peripheral blood mononuclear cells without modulating the
mRNA and the protein levels of calcineurin. PMA and Ca-
ionophore (A23187), the activating agents of PKC, applied
alone or in combination, significantly increased the phos-
phorylation state of Cabin 1 as revealed by immuno-
precipitation of Cabin 1 detecting its phospho-Ser content by
specific antibodies. GF109203X, an inhibitor of the classic
and the novel protein kinase C isoenzymes, and Gö6976, the
selective inhibitor of the classical cPKC isoenzymes were
able to abolish the effect of PMA or/and Ca-ionophore on the
calcineurin activity with concomitant reversal of the hyper-
phosphorylation of Cabin 1. The calcineurin/Cabin 1 system
was not influenced by Rottlerin, an inhibitor of PKC δ
isoenzyme either in the absence or in the presence of Ca-
ionophore and PMA. We presented evidence for the prominent
role of cPKC α, ß, γ isoenzymes in the inhibition of
calcineurin as induced by PMA and Ca-ionophore. We
demonstrated also that hyperphosphorylation of Cabin 1 by
PMA/Ca2+-activated cPKC isoenzymes resulted in a
simultaneous inhibition of calcineurin in peripheral blood
mononuclear cells. These results suggest a negative
regulatory role for Cabin 1 in calcineurin signalling and
provide a possible mechanism of feedback inhibition through
cross-talk between PKC and calcineurin.
Introduction
A consequence of T cell activation is an increase in the level
of second messengers inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). The calcium release induced by IP3
influences the activity of protein phosphatase 2B also termed
calcineurin. Calcineurin promotes the nuclear translocation
of NFAT (nuclear factor of activated T cells) by dephos-
phorylating the transcription factor. NFAT plays a prominent
role in the transcription of several genes of pro-inflammatory
cytokines including interleukin-2 (IL2), IL4, IL5, IL8, IL10,
tumour necrosis factor α (TNFα), interferon γ (IFNγ), cell
surface molecules (e.g. CD40 and ICAM), and Fas ligand
(1-3). Calcineurin plays essential roles in T cell receptor
(TCR)-mediated peripheral T cell activation, cell proliferation,
differentiation, and death. Its dependence on calcium and
calmodulin for the catalytic function is unique among all
known protein phosphatases, thus making it one of the
intracellular transducers of calcium signalling pathways. The
phosphatase activity of calcineurin depends on the binding of
Ca2+ to its regulatory subunit and the Ca2+-dependent binding
of calmodulin to the catalytic subunit of the enzyme (4-8).
Recently, a growing number of endogenous calcineurin-
binding proteins have been discovered which affect enzyme
activity. They are classified as dual regulators, anchoring
proteins and inhibitors of calcineurin. Calcineurin binding
protein (Cabin 1 or Cain) belongs to the group of endogenous
inhibitors of calcineurin, which results in the inhibition
of enzyme activity by binding to calcineurin through a
conserved motif PXIXIT also found in Cabin 1 as (PEITVT).
Cabin 1 is hypophosphorylated in non-activated T cells, and
in response to protein kinase C (PKC) activation, it becomes
hyperphosphorylated exhibiting a higher affinity for
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calcineurin. It has been reported that the interaction between
Cabin 1 and calcineurin requires both calcium signalling and
activation of PKC (8-10).
The enzymes of the PKC superfamily phosphorylate Ser
and Thr residues in many target proteins and play central
roles in the regulation of various cellular processes in
numerous cell types. To date, at least 11 different PKC
isoenzymes have been identified, which can be classified into
three major groups that differ in their cofactor requirements.
These are known as the conventional PKC (cPKC α, ßI, ßII,
and γ), the novel PKC (nPKC δ, ε, η, and θ), the calcium and
phorbol-ester-independent atypical PKC (aPKC ζ, and λ/ι)
isoforms, and the unique PKCμ. Both cPKCs and nPKCs can
be activated with phorbol ester, however, the most important
difference is that the nPKCs do not contain a Ca2+-binding
domain unlike cPKC, i.e. nPKCs are insensitive for Ca2+
signalling. These isoforms, possessing characteristic tissue
and cellular distribution, regulate in an isoform-specific
manner various cellular functions such as proliferation,
differentiation, cytokine production and release, and receptor-
mediated signal transduction (11,12). 
Systemic lupus erythematosus (SLE) is an autoimmune
disease. In SLE various abnormalities affecting signal
transduction pathways have been reported, for example
abnormal NF-κB (nuclear factor-κB) activity and
intracellular distribution of NFAT1, overproduction of pro-
inflammatory cytokines, decreased expression of TCR ζ
chain and PKC θ, and decreased PKC-dependent protein
phosphorylation (13-18). Previously, we studied the activity
of calcineurin in healthy and lupus T cells treated with
activating agents of PKC (5 μM of Ca-ionophore, A23187
and 80 nM phorbol-ester, PMA, phorbol-12-myristate-13-
acetate) in the presence or the absence of glucocorticosteroid
(GCS) mostly used for the treatment of SLE in the active
period of the disease. We reported a significant decrease in
calcineurin activity in peripheral blood mononuclear cells
(PBMC) from patients with SLE. It was demonstrated also
that the GCS-treatment of PBMC from healthy controls
exhibited lower calcineurin activity in the presence of Ca-
ionophore and PMA. Our observation suggested that the
PKC enzymes may play a role in the regulation of calcineurin
in T cells (19). 
In this study we aimed at investigating the possible role
of PKC isoenzymes upon stimulation by phorbol-ester and
Ca-ionophore in the inhibition of calcineurin in PBMC from
healthy controls. Furthermore, we also showed that the
inhibition of calcineurin is related to Cabin 1 hyperphos-
phorylated by PKC.
Materials and methods
Preparation of human peripheral blood mononuclear cells
(PBMC) and characterizations of cells by flow cytometry.
PBMC, containing 88-95% lymphocytes and 5-12%
monocytes, were prepared (20) from the heparinized blood of
healthy donors. The averages of various cellular subsets were
detected by flow cytometry: CD3+ 69.4%, CD19+ 11.5%,
CD56+ 0.8%, and CD14+ 8.3%. The suspension of mono-
nuclear cells (106 cells per sample) was labelled by saturating
concentrations of anti-CD3-FITC (T3, Coulter, Hialeah, FL,
USA), anti-CD19-RD1 (B4, Coulter), anti-CD56-PE (Leu-19,
Becton Dickinson, Mountain View, CA, USA), and anti-
CD14-RD1 (MY4, Coulter). After staining and fixing, the
cells were analyzed by a Coulter Epics XL flow cytometer
(Coulter).
Stimulation of PBMC. The cells (5x106 cells/ml) were
incubated with 5 μM of Ca-ionophore (A23187, Sigma, St.
Louis, MO) or/and 80 nM of phorbol-12-myristate 13-acetate
(PMA, Sigma) for 4 h in a CO2 incubator at 37˚C. For PKC
inhibition studies the cells were preincubated for 1 h with
various cell-permeable inhibitors [1 μM GF109203X, 200 nM
Gö6976, 10 μM Rottlerin (Calbiochem, EMD Bioscience
Inc., San Diego, CA)] prior to the treatment with Ca-ionophore
or/and PMA.
Viability assay. After the stimulation of PBMC, 2x106 cells/
100 μl were treated with alamarBlue according to the
manufacturer's instructions (BioSource International, Inc.,
Camarillo, CA). The cells were incubated in a CO2 incubator
at 37˚C for 45 min. Following the incubation, the fluorescence
of the alamarBlue was determined at 530-nm excitation and
at 590-nm emission by using Fluoroskan Acent Fl (Thermo
Labsystems, Stockholm, Sweden). The stimulating agents of
PKC had no significant effects on the arbitrary fluorescence
unit (AFU) measured in the samples. The means of the AFU
(3-4 independent experiments) with standard deviation
values were as follows: 3434±321 for the control, 3250±414
for PMA, 3688±395 for Ca-ionophore, and 3512±219 for
PMA and Ca-ionophore. The treatment of the samples with
GF109203X, Gö6976, and Rottlerin did not affect the values
of AFU determined in the absence and presence of stimulating
agents. 
Preparation of cell extracts. After the stimulation of PBMC,
cells were pelleted and washed thoroughly with PBS (20 mM
Na2HPO4 and 115 mM NaCl, pH 7.4), then suspended in
100 μl of homogenization buffer containing 50 mM Tris-HCl
buffer (pH 7.0), 0.5 mM dithiothreitol, 10 μg/ml Gordox, 10 μg/
ml leupeptin, 1 mM phenylmethylsulphonyl (PMSF), 5 mM
benzamidine, 10 μg/ml trypsin inhibitor as protease inhibitors,
and 0.5% Triton X-100. After freezing and storing at -70˚C,
thawed suspensions were sonicated by a pulsing burst four
times for 30 sec by 50 cycles (Branson Sonifier, Danbury, CT,
USA). The supernatants were used promptly for calcineurin
assays after centrifugation at 10,000 x g for 10 min at 4˚C.
For Western blot analysis, total cell lysates were used. For
RT-PCR analysis samples were washed three times with
nuclease-free physiological sodium chloride solution and
then the cultures were stored at -70˚C.
Assay of calcineurin. Calcineurin activity was measured by
the release of 32Pi from 32P-labelled protein phosphatase
inhibitor-1 (780 cpm/pmol) (21) with some modifications
(22). The assay mixture (30 μl) contained 50 mM Tris-HCl
buffer (pH 7.0), 0.16 mM dithiothreitol, 3.4 μg/ml Gordox,
3.4 μg/ml leupeptin, 1 mM PMSF, 1.6 mM benzamidine,
3.4 μg/ml trypsin inhibitor as protease inhibitors, 40 μg/ml
calmodulin, 0.2 mM CaCl2, 100 nM okadaic acid (OA), 2 nM
protein phosphatase inhibitor-2, an appropriate amount of
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cell extract (~80 μg protein/assay) and 32P-labelled protein
phosphatase inhibitor-1 (20,000-30,000 cpm/reaction
mixture). The assay mixtures were incubated at 30˚C for
20 min. The reaction was terminated by the addition of 100 μl
of 20% trichloroacetic acid and 100 μl of 6 mg/ml bovine
serum albumin (BSA, Sigma). After centrifugation the
radioactivity of the supernatant (180 μl) was determined in a
liquid scintillation counter.
RT-PCR analysis. Total RNA was isolated from cells using
an RNA isolation kit according to the manufacturer's
instruction (Gentra Systems Inc., Minneapolis, MN, USA).
The assay mixture for reverse transcriptase reaction
contained 2 μg RNA, 0.112 μM oligo(dT), 0.5 mM dNTP,
200 units M-MLV RT in 1X RT buffer. The sequences of the
primer pairs for polymerase chain reaction were as follows:
for human calcineurin, 5'-TAC CCT GCA GTT TGT GAA
TT-3' and 5'-ATA TGT TGA GCA CAT TTA CCA-3'; for
human GAPDH, 5'-CCA GAA GAC TGT GGA TGG CC-3'
and 5'-CTG TAG CCA AAT TCG TTG TC-3'. Amplifi-
cations were performed in a thermocycler (PCR Express
temperature cycling system, Hybaid, UK) as follows: 94˚C
for 1 min, followed by 30 cycles (94˚C for  30 sec, 54˚C for
30 sec and 72˚C for 30 sec) and then at 72˚C for 5 min. PCR
products were analyzed by electrophoresis in 1.2% agarose
gel containing ethidium bromide.
Immunoprecipitation of Cabin 1. After sonification of cell
suspensions, the samples were centrifuged at 13000 x g for
10 min at 4˚C, and the supernatants were used for immuno-
precipitation analysis. The immunoprecipitation buffer
contained 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1 mM Na3VO4, 1 mM NaF, 1% Triton X-100, 10 μg/
ml leupeptin, 1 mM PMSF, 5 mM benzamidine, and 10 μg/ml
trypsin inhibitor. Cell lysates containing 200 μg of protein
were incubated with 0.25 μg/ml anti-rabbit IgG antibody
(Sigma) and Protein A Sepharose (Sigma) for 2 h at 4˚C. After
centrifugation at 2000 x g for 1 min at 4˚C, the supernatants
were incubated with 5 μl anti-Cabin 1 antibody (Affinity
BioReagent, Golden, CO) for 2 h at 4˚C. Then 50 μl Protein
A Sepharose beads were added to the precleared samples
containing antibody-protein complexes and were incubated
overnight at 4˚C. After collecting the antigen-antibody-
protein A complexes by centrifugation at 1500 x g for 5 min
at 4˚C and discarding the supernatant, pellets were washed
three times with immunoprecipitation buffer. For SDS-
PAGE, antigen-antibody-protein A samples were prepared by
adding 1/2 volume of 2-fold-concentrated electrophoresis
sample buffer (124 mM Tris-HCl, pH 6.8, 4% SDS, 20%
glycerol, 40 mM DTT, 0.004% bromophenol blue) and
boiling for 5 min.
Western blot analysis. Samples for SDS-PAGE were
prepared by adding 1/5 volume of 5-fold-concentrated
electrophoresis sample buffer (310 mM Tris-HCl, pH 6.8,
10% SDS, 50% glycerol, 100 mM DTT, 0.01% bromophenol
blue) to the cell lysates and boiling for 10 min. Approximately
10-50 μg of proteins was separated by 10 or 5% SDS-PAGE
gel for calcineurin and Cabin 1, respectively. After the gel
electrophoresis, proteins were transferred electrophoretically
to a nitrocellulose membrane. After blocking with 5% non-
fat dry milk in PBST (20 mM Na2HPO4, 115 mM NaCl, 0.1%
Tween-20, pH 7.4), the membranes were washed and exposed
to the primary antibodies overnight at 4˚C. For detection of
phospho-Ser of Cabin 1, 3% BSA in PBST was used for
blocking. Monoclonal anti-calcineurin (α-subunit) primary
antibody (Sigma) in 1:300 dilution, polyclonal anti-Cabin 1
antibody (Affinity BioReagent) in 1:500 dilution, and
monoclonal anti-phospho-Ser antibody (Calbiochem, EMD
Bioscience Inc., San Diego, CA) in 1:50 dilution were used.
After washing three times for 10 min with PBST, the
membranes were incubated with the second antibody, anti-
mouse IgG (Sigma) in 1:2000 dilution for calcineurin and
phospho-Ser, and anti-rabbit IgG (Sigma) in 1:2000 dilution
for Cabin 1. The dilution was conducted in PBST containing
1% non-fat dry milk for calcineurin and Cabin 1 and 1% BSA
for phospho-Ser. The signal was detected by enhanced
chemiluminescence (Amersham Pharmacia Biotech, UK).
Statistical analysis. Statistical means and standard error of
the mean (SEM) values were evaluated by the Student's t-test.
For the densitometric analysis of mRNA and protein levels,
each value was calculated as the mean of the data from 3-6
healthy control subjects. The evaluation and statistics of
optical densities are based on 3 independent experiments
(RT-PCR and Western blots).
Results
Effect of various protein kinase C inhibitors on the
calcineurin activity of human PBMC stimulated by phorbol-
ester. PKC inhibitors were used as follows: GF109203X
(GF), an inhibitor of the classic and the novel; Gö6976 (Gö),
an inhibitor of the classic; and Rottlerin (Ro), an inhibitor of
the δ type of PKC isoenzymes. None of the three PKC
inhibitors were found to have any significant effect on the
activity of calcineurin in the absence of PMA (Fig. 1).
Stimulation of cells with PMA resulted in a significant
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Figure 1. Calcineurin activities in PBMC of healthy donors treated with
PMA and various PKC inhibitors. The effect of 80 nM PMA on the activity
of calcineurin in the absence (open columns) and presence (hatched
columns) of PKC inhibitors (1 μM GF, 0.2 μM Gö, 10 μM Ro). Data
represent the average values ± SEM of 4-6 independent experiments.
Calcineurin activity in PBMC stimulated with PMA was compared to
the non-stimulated control, while the effect of PKC inhibitors on the
phosphatase activity was compared to the non-stimulated and PMA-treated
controls, respectively. Significant differences are shown as *p<0.05,
**p<0.01, and ***p<0.001. Calcineurin assay and the conditions of stimulation
can be found in Materials and methods.
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decrease in calcineurin activity as compared to the non-
stimulated control (68 versus 100%). This reduced calcineurin
activity was elevated in PMA-treated samples when
GF109203X and Gö6976 were also applied. On the other
hand, Rottlerin did not restore the reduced enzymatic activity
of calcineurin.
Effect of various PKC inhibitors on the activity of calcineurin
in human PBMC stimulated by Ca-ionophore with or without
PMA. Similar to PMA, Ca-ionophore stimulation also resulted
in a significant decrease in the activity of calcineurin (58
versus 100%). Moreover, this was a slightly higher reduction
than that observed in the presence of PMA. There was no
significant change in the calcineurin activity of PBMC
simultaneously treated with both activating agents as
compared to the enzyme activity of PBMC stimulated with
Ca-ionophore alone. PKC inhibitors, GF109203X and
Gö6976, reversed the phosphatase activity in the stimulated
cells approximately with the same efficacy, while Rottlerin
had no effect under these conditions (Fig. 2). It is known that
GF109203X is a less selective inhibitor of PKC isoenzymes
than Gö6976. Gö6976, a selective inhibitor of cPKC iso-
enzymes, alone was able to counteract the inhibition of
calcineurin suggesting the involvement of cPKC α, ß, γ iso-
enzymes in the PMA- and/or Ca-ionophore-induced changes.
RT-PCR and Western blot analyses of mRNA and protein
levels of calcineurin in human PBMC. The RT-PCR and
Western blot analysis indicated that neither PMA nor Ca-
ionophore applied alone modified the mRNA and protein
levels of the enzyme (Figs. 3 and 4). The combined application
of PMA and Ca-ionophore resulted in a 20% decrease in the
mRNA level of calcineurin as compared to the non-stimulated
control. However, it was not a significant change and had no
appreciable effect on the protein level of calcineurin. Gö6976,
an inhibitor of cPKC isoenzymes, slightly increased the
mRNA level of calcineurin in the presence of PMA and Ca-
ionophore as compared to that of the stimulated PBMC
although the statistical analysis failed to show any significant
change (Fig. 3). The above data imply that the decrease in the
calcineurin activity of PBMC treated with PMA and Ca-
ionophore is not due to the inhibition of transcription or
translation of calcineurin.
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Figure 2. Calcineurin activities in the PBMC of healthy donors treated with
Ca-ionophore, PMA, and various PKC inhibitors. Samples were stimulated
with 5 μM Ca-ionophore in the absence (hatched columns) or in the
presence of 80 nM PMA (filled columns) using the same concentrations of
PKC inhibitors as given in Fig. 1. Data represent the average values ± SEM
of 4-6 independent experiments. Calcineurin activity in PBMC stimulated
with Ca-ionophore was compared to the non-stimulated control, while
samples treated with Ca-ionophore and PMA were compared to the enzyme
activity of PBMC stimulated with Ca-ionophore. The effect of PKC
inhibitors on the calcineurin activity was compared to that of PBMC treated
with Ca-ionophore in the presence or absence of PMA, respectively.
Significant differences are shown as *p<0.05, **p<0.01, and ***p<0.001.
Calcineurin assay and the conditions of stimulation can be found in
Materials and methods.
Figure 3. RT-PCR analyses of calcineurin and GAPDH mRNAs from the
PBMC of healthy donors. (A) Representative mRNA values for calcineurin
in PBMC treated with PMA, Ca-ionophore, and PKC inhibitors.
Concentrations were the same as those given in Figs. 1 and 2. (B) Optical
density of calcineurin mRNAs representing the average values with standard
error of the mean of 3 independent experiments. The RT-PCR assay and the
conditions of stimulation are given in Materials and methods.
Figure 4. Western blot analyses of calcineurin in the PBMC of healthy
patients. (A) Immunoblot of calcineurin in the presence of various effectors.
Concentrations of effectors were the same as used in experiments shown in
Figs. 1 and 2. (B) Optical density of the protein level of calcineurin showing
the average values with standard error of the mean of 3 independent
experiments. No significant changes were found in the various samples.
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Cabin 1 as a signal transducer between PKC and calcineurin.
As the phosphorylation of calcineurin by PKC does not affect
its enzymatic activity (23,24), one can suppose that an
upstream signal transduction molecule activated by PKC is
involved in the reduction of calcineurin activity. It has been
reported that in response to PKC activation Cabin 1 becomes
hyperphosphorylated exhibiting a higher affinity for calci-
neurin, and the binding of Cabin 1 to the enzyme inhibits its
activity (7,9). To investigate the possible role of Cabin 1 in
this signalling pathway, Cabin 1 was immunoprecipitated
with a polyclonal antibody. After immunoprecipitation the
protein level of Cabin 1 and its phosphorylation state on Ser
residues were analyzed by immunoblotting. As shown in
Fig. 5 the phosphorylation state of Cabin 1 was remarkably
enhanced by activating agents of PKC applied alone or in
combination. On the other hand, PKC inhibitors (GF109203X
and Gö6976) significantly reduced the hyperphosphorylation
of Cabin 1, and Rottlerin had no effect on the hyperphos-
phorylation of Cabin 1 as compared to the data of stimulated
PBMC.
Discussion
Our observation suggests that both PMA and Ca2+ treatments
contribute to the decrease of calcineurin activity of T cell-
enriched PBMC without modulating the mRNA and protein
levels of calcineurin. The present data also showed that
several PKC isoenzymes play active roles in the inhibition of
the activity of calcineurin in human PBMC stimulated by
PMA and Ca-ionophore. The use of cell-permeable PKC
inhibitors suggests that the cPKC α, ß, γ isoenzymes are
involved in the inhibition of the enzyme. Gö6976, the
selective inhibitor of cPKC isoenzymes, was able to reverse
the inhibitory effect of PMA and Ca-ionophore applied alone
or in combination on the calcineurin activity. There are some
endogenous protein inhibitors of calcineurin including Cabin
1 which are activated by hyperphosphorylation in response to
PKC activation. Hyperphosphorylated Cabin 1 gains higher
affinity for calcineurin, thus Cabin 1 may be responsible for
dampening calcineurin activity in the course of T cell
activation (7,9,10). Our data also confirmed that Cabin 1 may
be a transducer which mediates the PKC signalling towards
calcineurin, as an increasing phosphorylation state of Cabin 1
was observed in response to the stimulation by Ca-ionophore
and PMA. The hyperphosphorylation of Cabin 1 was
suppressed in the presence of GF109203x and Gö6976,
inhibitors of cPKC and nPKC. It has been shown that the
interaction between Cabin 1 and calcineurin requires both
calcium signalling and activation of PKC. It has also been
demonstrated that PMA treatment of Jurkat cells leads to
hyperphosphorylation of Cabin 1, while ionomycin did not
change the phosphorylation state of this protein (7,10).
However, we failed to detect a decrease in calcineurin activity
in Jurkat cells treated with PMA and Ca-ionophore (data not
shown). It has also been reported that the autophosphorylated
calcium/calmodulin-dependent protein kinase II (CaM kinase
II) is able to phosphorylate calcineurin inhibiting its phos-
phatase activity in vitro (23,24). Phospho amino acid sequence
analysis confirmed that PKC and CaM kinase II phos-
phorylated the same site (25). These results may suggest a
role of CaM kinase II in the calcineurin and PKC-dependent
signalling system. Further experiments are required to
elucidate the lack of inhibition of calcineurin in a T cell line
and to demonstrate the possible role of other protein kinases
in the regulation of calcineurin activity.
A number of signalling molecules in SLE T cells have
been reported to malfunction, including transcription factor
elf-1, inflammation signal transducer NF-κB and PKC θ (18).
It has been shown that the treatment of the healthy and lupus
T cells with GCS decreased the activity of calcineurin and
elevated the expression of most isoforms of PKC close to the
normal values (19,26). In this study we provided evidence for
the transducer role of hyperphosphorylated Cabin 1 between
the increase of PKC activation and the decrease of calci-
neurin activity in PBMC from healthy patients. It is known
that in T cells the NFAT/calcineurin pathway is involved in
the induction of pro-inflammatory cytokines, and lupus T
cells have a major role in the pathogenesis of SLE via
overproduction of cytokines (IL2, IL4, IL5, IL8, IL10). Our
data show that the calcineurin/NFAT signal transduction
pathway, i.e. the overexpression of pro-inflammatory
cytokines, is able to be suppressed through the activation of
hyperphosphorylated Cabin 1 via cPKC α, ß, γ isoenzymes.
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Figure 5. Western blot analysis of Cabin 1 and the phosphorylation level of
Ser residues after the immunoprecipitation of Cabin 1. (A) Immunoblot of
Cabin 1 and the detection of phospho-Ser from non-stimulated and
stimulated PBMC in the presence of various effectors. Concentrations of
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(B) Optical density of phospho-Ser in Cabin 1 representing the average
values with standard error of the mean of 3 independent experiments.
Significant differences are shown as *p<0.05. Detection of Western blots
and the immunoprecipitation of Cabin 1 can be found in Materials and
methods.
359-364  25/7/07  10:31  Page 363
Zsanett Molnár, and Miss Andrea Fekete for the excellent
technical assistance. This study was supported by grants from
the Hungarian Science Research Fund (OTKA K60620) and
the Hungarian Ministry of Health (ETT 083/2006). Zsolt
Szíjgyártó is currently a recipient of a fellowship from the
Hungarian Academy of Sciences.
References
1. Kiani A, Rao A and Aramburu J: Manipulating immune
responses with immunosuppressive agents that target NFAT.
Immunity 12: 359-372, 2000.
2. Hogan PG, Chen L, Nardone J and Rao A: Transcriptional
regulation by calcium, calcineurin, and NFAT. Genes Dev 17:
2205-2232, 2003.
3. Feske S, Okamura H, Hogan PG and Rao A: Ca2+/calcineurin
signalling in cells of the immune system. Biochem Biophys Res
Commun 311: 1117-1132, 2003.
4. Aramburu J, Rao A and Klee CB: Calcineurin: from structure to
function. Curr Top Cell Regul 36: 237-295, 2000.
5. Klee CB, Ren H and Wang X: Regulation of the calmodulin-
stimulated protein phosphatase, calcineurin. J Biol Chem 273:
13367-13370, 1998.
6. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I and
Schreiber SL: Calcineurin is a common target of cyclophilin-
cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815,
1991.
7. Liu JO: Endogenous protein inhibitors of calcineurin. Biochem
Biophys Res Commun 311: 1103-1109, 2003.
8. Rusnak F and Mertz P: Calcineurin: form and function. Physiol
Rev 80: 1483-1521, 2000.
9. Lai MM, Burnett PE, Wolosker H, Blackshaw S and Snyder SH:
Cain, a novel physiologic protein inhibitor of calcineurin. J Biol
Chem 273: 18325-18331, 1998.
10. Sun L, Youn HD, Loh C, Stolow M, He W and Liu JO: Cabin 1,
a negative regulator for calcineurin signaling in T lymphocytes.
Immunity 8: 703-711, 1998.
11. Mellor H and Parker PJ: The extended protein kinase C
superfamily. Biochem J 332: 281-292, 1998.
12. Toker A: Signaling through protein kinase C. Front Biosci 3:
1134-1147, 1998.
13. Fujii Y, Fujii K, Iwata S, Suzuki K, Azuma T, Saito K and
Tanaka Y: Abnormal intracellular distribution of NFAT1 in T
lymphocytes from patients with systemic lupus erythematosus
and characteristic clinical features. Clin Immunol 119: 297-306,
2006.
14. Fujii Y, Fujii K and Tanaka Y: Attempt to correct abnormal
signal transduction in T lymphocytes from systemic lupus
erythematosus patients. Autoimmun Rev 5: 143-144, 2005.
15. Solomou EE, Juang YT, Gourley MF, Kammer GM and
Tsokos GC: Molecular basis of deficient IL-2 production in T
cells from patients with systemic lupus erythematosus. J
Immunol 166: 4216-4222, 2001.
16. Tada Y, Nagasawa K, Yamauchi Y, Tsukamoto H and Niho Y:
A defect in the protein kinase C system in T cells from patients
with systemic lupus erythematosus. Clin Immunol Immunopathol
60: 220-231, 1991.
17. Wong HK, Kammer GM, Dennis G and Tsokos GC: Abnormal
NF-kappa B activity in T lymphocytes from patients with
systemic lupus erythematosus is associated with decreased p65-
RelA protein expression. J Immunol 163: 1682-1689, 1999.
18. Takeuchi T, Tsuzaka K, Abe T, Yoshimoto K, Shiraishi K,
Kameda H and Amano K: T cell abnormalities in systemic lupus
erythematosus. Autoimmunity 38: 339-346, 2005.
19. Sipka S, Szucs K, Szanto S, et al: Glucocorticosteroid dependent
decrease in the activity of calcineurin in the peripheral blood
mononuclear cells of patients with systemic lupus erythematosus.
Ann Rheum Dis 60: 380-384, 2001.
20. Boyum A: Isolation of mononuclear cells and granulocytes from
human blood. Isolation of monuclear cells by one centrifugation,
and of granulocytes by combining centrifugation and
sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89,
1968.
21. Cohen P, Foulkes JG, Holmes CF, Nimmo GA and Tonks NK:
Protein phosphatase inhibitor-1 and inhibitor-2 from rabbit
skeletal muscle. Methods Enzymol 159: 427-437, 1988.
22. Zakany R, Szijgyarto Z, Matta C, et al: Hydrogen peroxide
inhibits formation of cartilage in chicken micromass cultures
and decreases the activity of calcineurin: implication of ERK1/2
and Sox9 pathways. Exp Cell Res 305: 190-199, 2005.
23. Hashimoto Y, King MM and Soderling TR: Regulatory
interactions of calmodulin-binding proteins: phosphorylation of
calcineurin by autophosphorylated Ca2+/calmodulin-dependent
protein kinase II. Proc Natl Acad Sci USA 85: 7001-7005,
1988.
24. Hashimoto Y and Soderling TR: Regulation of calcineurin by
phosphorylation. Identification of the regulatory site phos-
phorylated by Ca2+/calmodulin-dependent protein kinase II and
protein kinase C. J Biol Chem 264: 16524-16529, 1989.
25. MacNicol M and Schulman H: Cross-talk between protein
kinase C and multifunctional Ca2+/calmodulin-dependent protein
kinase. J Biol Chem 267: 12197-12201, 1992.
26. Biro T, Griger Z, Kiss E, Papp H, et al: Abnormal cell-specific
expressions of certain protein kinase C isoenzymes in peripheral
mononuclear cells of patients with systemic lupus erythematosus:
effect of corticosteroid application. Scand J Immunol 60: 421-428,
2004.
SZÍJGYÁRTÓ et al:  REGULATION OF CALCINEURIN BY PROTEIN KINASE C364
359-364  25/7/07  10:31  Page 364
